US Stock MarketDetailed Quotes
GLTO Galecto
- 5.370
- -0.290-5.12%
Close Dec 11 16:00 ET
- 5.400
- +0.030+0.56%
Post 17:24 ET
7.07MMarket Cap-0.28P/E (TTM)
5.740High5.260Low22.57KVolume5.740Open5.660Pre Close121.65KTurnover1.86%Turnover RatioLossP/E (Static)1.32MShares23.50052wk High0.34P/B6.51MFloat Cap5.26052wk Low--Dividend TTM1.21MShs Float449.750Historical High--Div YieldTTM8.48%Amplitude5.260Historical Low5.388Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Galecto Stock Forum
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
@FiReBiTriXiE @jimmy the trader @MangoXXX @PYUN970IHaveChosen @Ripper @Rivera @Trytosaveabit @VinylEagle @Wind_Storm @8 Seconds
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AH volume 1.2M and growing
positive trial data 👍
2 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
No comment yet